| 2017-LOW-67871 | |
| Cancer is a deadly disease that affects many people around the world. However, current chemotherapy is associated with a litany of unwanted side effects. In addition, existing treatment does not diagnose malignant stages fast enough for effective treatment. There is need of a method for reducing both the time of diagnosis and the side effects associated with traditional chemotherapy. Researchers at Purdue University have developed a small molecule drug conjugate (SMDC) for cancer treatment. The drug would provide an option for patients who want to achieve early diagnosis and better treat tumors by avoiding the many side effects of traditional chemotherapy like nausea and hair loss. This drug would target chemotherapy drugs and radioimaging agents to help oncologists treat cancer patients in early malignant stages. Advantages: -Reduced side effects -Early diagnosis Potential Applications: -Chemotherapy drugs -Radioimaging agents |
|
|
|
|
Feb 20, 2020
NATL-Patent
United States
11,524,082
Dec 13, 2022
Apr 20, 2023
DIV-Patent
Japan
(None)
(None)
Dec 30, 2020
EP-Patent
Hong Kong
(None)
(None)
Dec 2, 2020
EP-Patent
Hong Kong
(None)
(None)
Feb 21, 2020
NATL-Patent
Japan
(None)
(None)
Aug 21, 2018
PCT-Patent
WO
(None)
(None)
Aug 21, 2018
NATL-Patent
Europe
(None)
(None)
Aug 21, 2018
NATL-Patent
China
(None)
(None)
Aug 22, 2017
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
